The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 3, under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2025.

Siemens Healthineers and Evident said Wednesday that they are partnering on the delivery of a digital pathology workflow to the German nonprofit teaching hospital Klinikum der Stadt Ludwigshafen am Rhein.

Cyted Health, a leading gastrointestinal (GI) molecular diagnostics company, today announces a first close of $44 million in its Series B financing round to accelerate its ongoing US expansion.

Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced the closing of a $59 million series B financing. The round was co-led by Novalis and Sozo Ventures, with participation from Perceptive Xontogeny Venture Funds, American Cancer Society BrightEdge, and iSelect Fund, as well as funds committed to women’s health and leadership including Portfolia, Avestria Ventures, and Mindshift Capital. The round also included significant participation from strategic investors including Hologic, Bruker Scientific, and Labcorp.

Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer. MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify mismatch repair (MMR) deficient CRC patients eligible for treatment with OPDIVO® (nivolumab) in combination with YERVOY® (ipilimumab). MMR IHC Panel pharmDx (Dako Omnis) is approved for exclusive use with the Agilent Dako Omnis automated staining solution.

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced the completion of its acquisition of Sanofi’s state-of-the-art sterile fill-finish and packaging site in Ridgefield, New Jersey, marking an expansion of the companies’ strategic partnership to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. The Ridgefield facility is now part of Thermo Fisher's pharma services business within its Laboratory Products and Biopharma Services segment.

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced the completion of its acquisition of the Purification & Filtration business of Solventum (NYSE: SOLV) for approximately $4.0 billion in cash. With the transaction complete, the business, which is now Thermo Fisher’s Filtration and Separation business, is part of the Life Sciences Solutions segment.

Coagulation analyzers are mainly applied for laboratory tests of thrombosis and hemostasis, which can provide valuable indicators for the diagnosis and differential diagnosis of hemorrhagic and thrombotic diseases, detection, and efficacy of thrombolytic and anticoagulant therapy.

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers unparalled throughput with the easiest workflow available to customers worldwide.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.